Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Cardiff Oncology, Inc. (CRDF)
Company Research
Source: Yahoo! Finance
biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, announced that in connection with Dr. Aggarwal joining Cardiff Oncology as Chief Operating Officer, the Company's Compensation Committee approved the grant of non-qualified stock options to purchase 400,000 shares of Cardiff Oncology common stock outside of the Cardiff Oncology 2021 Omnibus Equity Incentive Plan. The stock option was granted as an inducement material to Dr. Aggarwal becoming an employee of Cardiff Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The option was granted as of April 27, 2026, and has an exercise price of $1.72 per share, the closing price on the grant date. The option vests over four years with 25% vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to Dr. Aggarwal's continued employment with Cardiff Oncology on such vesting dates. About Cardiff Oncology, Inc. Cardiff Oncology is a clinic
Show less
Read more
Impact Snapshot
Event Time:
CRDF
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRDF alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRDF alerts
High impacting Cardiff Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
CRDF
News
- Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent ActivityGlobeNewswire
- Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026GlobeNewswire
- Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual MeetingGlobeNewswire
CRDF
Earnings
- 2/24/26 - Miss
CRDF
Sec Filings
- 4/28/26 - Form 4
- 4/28/26 - Form 3
- 4/23/26 - Form DEF
- CRDF's page on the SEC website